http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020323946-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf1aa7a6105ecdd03e09425cd6392753 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 |
| filingDate | 2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0de86dd009b53b2ac5970c690efa590c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_971272000e9dbdaa4e180982b789b044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ad94d8d4bde6bd69848f9058c7c0385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a20c201c1ee827eea6b77df031a7b66d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0962b4017aaefd3dfb04e7310b36f9f |
| publicationDate | 2020-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020323946-A1 |
| titleOfInvention | Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis |
| abstract | Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models. |
| priorityDate | 2013-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 245.